中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

59 records (took 0.048 seconds)

    VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    21.
    发明申请
    VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT 审中-公开

    公开(公告)号：US20180221470A1

    公开(公告)日：2018-08-09

    申请号：US15823852

    申请日：2017-11-28

    Applicant: Infectious Disease Research Institute

    Inventor： Steven G. Reed ,  Darrick Carter

    IPC: A61K39/39 ,  A61K9/107 ,  A61K39/00 ,  A61K39/145 ,  A61K39/04 ,  A61K39/008 ,  A61K45/06 ,  A61K39/35

    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

    RIG-I AGONIST AND ADJUVANT FORMULATION FOR TUMOR TREATMENT
    29.
    发明申请
    RIG-I AGONIST AND ADJUVANT FORMULATION FOR TUMOR TREATMENT 有权

    公开(公告)号：US20220396797A1

    公开(公告)日：2022-12-15

    申请号：US17777255

    申请日：2020-11-13

    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE

    Inventor： Malcolm S. DUTHIE ,  Steven G. REED

    IPC: C12N15/117 ,  A61P35/00 ,  A61K9/107

    Abstract: Cancer immunotherapies effective for treating tumors are disclosed. A cytosolic receptor that detects viral ribonucleic acid (RNA), retinoic-acid-inducible protein 1 (RIG-I), is activated by a synthetic double-stranded oligonucleotide pUUC Auk. In one implementation, RIG-I is activated by a single-stranded oligonucleotide agonist formulated with a squalene emulsion (SE) adjuvant. Activation of RIG-I with pUUC Auk results in slower tumor growth. Formulation with a SE adjuvant increases the ability of RIG-I agonists to slow tumor growth. The novel agonist and formulations provided herein are effective for slowing the growth of new tumors and reducing further growth of established tumors. RIG-I agonist/adjuvant formulations may be administered to a subject by any of multiple routes including intratumoral injection.

Patent Agency Ranking